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In Situ.-Generated Thrombin Is the Only Enzyme That Effectively Activates
Factor VIII and Factor V in Thromboplastin-Activated Plasma
By Jean Pieters, Theo Lindhout, and H. Coenraad Hemker
We investigated the activation of the nonenzymatic protein
cofactors factor VIII and factor V in plasma when coagula-
tion was initiated by thromboplastin. With sensitive bioas-
says, we were able to measure specifically the generation
of activated factor VIII and activated factor V in plasma.
Our results showed that when plasma was triggered with a
relatively high concentration of thromboplastin, factor VIII
and factor V were completely activated at the clotting time
of plasma. However, when the generation of thrombin, but
not that of factor Xa. was delayed by addition of hirudin to
C LOTTING OF PLASMA is the result of a series of
enzymatic reactions acting in a cascade 5ystem.’ Start-
ing either from the intrinsic or extrinsic coagulation path-
way, the coagulation system comprises a number of feedback
reactions (eg, generation of thrombin through the intrinsic
pathway proceeds only at a considerable rate after the
nonenzymatic protein cofactors factor V and factor VIII
have been activated.2’3 Activated factor VIII serves as an
essential cofactor for activation of factor X by factor IXa,
whereas factor Va plays the same role in the conversion of
prothrombin into thrombin by factor Xa.
Conversion of factor VIII into its activated form is
believed to proceed principally through the proteolytic activ-
ity of thrombin,4 although factor Xa is also considered a
possible important activator of factor VIII. Activation of
factor VIII by factor IXa has been demonstrated in a
purified system. However, the factor IXa concentrations
used in this study exceeded the plasma factor IX concentra-
tion, making it unlikely that factor IXa is physiologically
important for this activation.7
Thrombin and factor Xa have been demonstrated to
activate factor V.8’9 However, the thrombin-catalyzed activa-
tion of factor V appeared to be, on a molar basis, 100-fold
faster than the factor Xa-catalyzed reaction.9 Proteases
present in platelets and endothelial cells have also been
shown to activate factor V, although it is not clear if these
activation reactions occur under physiologic conditions.  2
The relative importance of these activators for in vivo
hemostasis is not clear. Thus, although a number of enzymes
have been described to activate factor VIII and factor V in
purified systems, the relative catalytic efficiencies of these
enzymes in plasma are unknown. Therefore, we investigated
generation of activated factor V and activated factor VIII
under more physiologic conditions, ie, thromboplastin-
activated plasma. With very specific bioassays, we were able
to follow the generation of factor Va and factor VIlla during
plasma coagulation. With hirudin, we were able to separate
thrombin generation from factor Xa generation and clearly
demonstrated that in this system thrombin is the only
enzyme responsible for activation of both factor V and factor
VIII.
MATERIALS AND METHODS
The synthetic peptide substrates Bz-Ile-Glu-(piperidyl)-Gly-Arg-
p-nitro-anilide hydrochloride (5-2337) and H-D-phenylalanyl-L-
the plasma, factor Va was generated only at the time
thrombin generation overcame the hirudin inhibition. In
addition, generation of factor VIlla correlated with throm-
bin generation and not with factor Xa generation. Further-
more, addition of large amounts of factor Xa to hirudinized
plasma did not show detectable factor VIII or factor V
activation. We concluded that in plasma activated with
thromboplastin the enzyme responsible for activation of
factor V and factor VIII is thrombin, not factor Xa.
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pipecolyl-L-arginine-p-nitro-anilide dihydrochloride (5-2238) were
purchased from AB Kabi, Stockholm. Ovalbumin was a product of
Sigma Chemical, St Louis. All reagents used were of the highest
grade commercially available. Human brain thromboplastin was
prepared by the method of Owren and Aas.’3 It was homogenated in
a Potter Elvehjem homogenizer for three minutes, centrifuged at
2,000 g for I 5 minutes, and stored at - 80#{176}C.Its concentration was
adjusted with Tris-saline (50 mmol/L Tris, 180 mmol/L NaCI, pH
7.9) to give a prothrombin time of 13 s.
Proteins. Recombinant desulfato-hirudin variant I (CG P
39393) was provided by Dr Wallis, Ciba-Geigy, Horsham, England.
All bovine clotting factors were prepared and quantitated as previ-
ously  Human factor Xa was purified according to the
method of Mertens and Bertina.” Its molar concentration was
determined by active-site titration with p-nitrophenyl p-guanidino-
benzoate hydrochloride.’5
Phospholipid. Phospholipid vesicles were made from a mixture
of phosphatidylserine (PS) and phosphatidylcholine (PC) as previ-
ously described.’5 Vesicles composed of 25 molar percent PS and 75
molar percent PC were used throughout the experiments.
Preparation of human normal plasma. Blood from healthy
donors was collected on 0. 13 mol/L trisodium citrate: nine parts
blood to one part citrate solution. The blood was then centrifugated
twice at room temperature for 1 5 minutes at 3,000 g. A third
centrifugation was performed at 4#{176}Cfor one hour at 23,000 g. The
obtained platelet-free plasma was stored at - 80#{176}C.
Thromboplastin-inducedfactor Xa. factor Va. factor VIlla. and
thrombin generation in platelet-free plasma. To 0. 1 3 mL citrated
human plasma, 9 iL Tris buffer (50 mmol/L Tris, 180 mmol/L
NaCI, 0.5 mg ovalbumin/mL, pH 7.9) with or without hirudin was
added and incubated for four minutes in a flat-bottom plastic tube
while the mixture was stirred. Clotting was initiated by addition of
1 1 zL Tris buffer containing 0.27 mol/L CaCl2 and human brain
thromboplastin. Timed samples (10 L) were removed from incuba-
tions and assayed for either factor Va, factor Xa, or thrombin
activity.
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Fig 2. Effect of hirudin on thrombin generation (A) and factor
Xa generation (B) in thromboplastin-activated plasma. Concentra-
tions of hirudin used were 0 (#{149}),300 (A), and 450 nmol/L (A).
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Factor Va assay. Factor Va was assayed in plasma samples,
diluted 1:200 in Tris buffer (pH 7.9) containing 5 mmol/L CaCI2
and 0.5  heparin/mL. Ten microliters of the diluted sample was
added to a cuvette containing 13 pmol/L factor Xa, 5 mmol/L
CaCl2, and 0.05 mmol/L phospholipid (25 molar percent phosphati-
dylserine and 75 molar percent phosphatidylcholine) in Tris buffer.
After four minutes, thrombin generation was initiated by addition of
prothrombin (0.2 imol/L final concentration in 125 ML). The
reaction was stopped after two minutes by addition of 325 zL Tris
buffer containing 20 mmol/L EDTA. The amount of thrombin was
measured in a dual-wavelength spectrophotometer using 5-2238 as
described previously.’7
Factor VIlla assay. Factor Villa was assayed in plasma sam-
pies diluted 1:40 directly into the assay mixture containing 100
nmol/L bovine factor IXa, 0.02 mmol/L phospholipid, 5 mmol/L
CaCl2, and 0.5 mg/mL ovalbumin in Tris buffer (pH 7.9). The
reaction was started after I 5 seconds on addition of bovine factor X
(final concentration 0.5 imol/L). At 30 and 90 seconds, 50 zL was
removed and assayed for factor Xa activity with the chromogenic
substrate 5-2337. From these two time points, the rate of factor X
activation was determined to be linear with the added amounts of
factor VIlla.
Factor Xa assay. Factor Xa was assayed in plasma samples
diluted 1:200 in Tris buffer (pH 7.9). Ten microliters of the diluted
sample was added to a cuvette containing 0.6 nmol/L factor Va, 0.05
mmol/L phospholipid, and 5 mmol/L CaCl2 in Tris buffer. After
four minutes, prothrombin (1 .5 izmol/L final concentration in 50
L) was added, and the assay was continued as described for factor
Va.
Thrombin assay. Undiluted plasma samples (5 giL) were added
to a cuvette containing 495 ML Tris buffer, 20 mmol/L EDTA, and
0.25 mmol/L 5-2238. The thrombin activity was calculated from the
RESULTS
Factor Villa bioassay. To determine activated factor
VIII in plasma, a highly sensitive and specific bioassay was
developed making use of the activity of factor Villa as an
essential cofactor in activation of factor X by factor IXa in
the presence of phospholipids and calcium. By judicious
choice of the concentrations of the reaction components, we
could measure factor Villa activity without interference of
nonactivated factor VIII. Figure 1 shows the calibration
curve constructed from a series of plasma dilutions activated
with thrombin (50 nmol/L). Assuming that the plasma
concentration of factor VIII is - 1 nmol/L,’”8 this assay is
shown to be linear up to 40 pmol/L factor VIlla and
concentrations as low as 5 pmol/L can be easily determined.
The intersection at the ordinate represents the activity of the
assay without factor VIII(a). Figure 1 shows the activity of
plasma not activated with thrombin (ie, the baseline value of
the assay). Control experiments with factor VIII-deficient
plasma showed that factor Xa generation in our assay
occurred only in the presence of activated factor VIII.
Effect of hirudin on thrombin and factor Xa genera-
lion. To investigate the relative importance of thrombin
and factor Xa to activation of factor V and factor VIII, we
first had to obtain in our plasma system nonoverlapping
thrombin and factor Xa generation curves. Therefore, we
incubated plasma with hirudin and activated it using a
thromboplastin concentration of 1 /30 (vol/vol). Thrombin
generation and factor Xa generation were determined as
FACTOR Villa, pM
Fig 1 . Calibration curve for factor VIlla (a)). Human normal
plasma was diluted to obtain the concentrations of factor VIII as
indicated, assuming that the concentration of plasma factor VIII is
1 nmol/I. The (diluted) plasma samples were activated with 50
nmol/I thrombin, and the activity was determined as described in
the Materials and Methods section. The activity of plasma not
activated with thrombin was also determined (A).
described in the Materials and Methods section. Figure 2
shows the effect of the addition of different amounts of
hirudin on thrombin and factor Xa generation. The thrombin
generation curve without hirudin is characterized by a very
short lag period followed by an explosive thrombin genera-
tion. The amidolytic activity decayed rapidly until a plateau
was reached. This residual activity is the result of the
formation of a thrombin-a2-macroglobulin complex.’9 Fig-
ure 2A shows that the more hirudin present, the more the
thrombin generation is delayed, and the maximum amount
of amidolytic active thrombin formed is also decreased.
Factor Xa generation and inactivation, as shown in Fig 2B, is
not affected by hirudin.
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Fig 3. Effect of hirudin on factor Va generation (A) and factor
VIlla generation (B) in thromboplastin-activated plasma. Concen-
trations of hirudin used were 0 (#{149}).300 (A). and 450 nmol/L (A).
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Effect of hirudin on factor Va and factor Villa genera-
tion. Figure 3A shows factor Va generation curves as
obtained when plasma was activated with thromboplastin
with varying amounts of hirudin added. Apparently, factor
Va generation is closely correlated with thrombin generation
but not at all with factor Xa generation. As in the case of
thrombin generation, increasing amounts of hirudin caused a
prolongation of the lag-phase of factor Va generation.
Despite a drastic decrease of the thrombin peak activity with
increasing hirudin, maximal factor Va activities could be
generated. Like the factor Va generation curves, the factor
Villa generation curves (Fig 3B) showed a very rapid
activation phase followed by a decay of factor Villa activity.
In protein C-depleted plasma, factor Va was not macti-
vated.#{176}Whether rapid decay of factor Villa is also due to
inactivation by activated protein C remains to be established.
Factor Villa generation is closely correlated with thrombin
generation but not with factor Xa generation.
Exogenousfactor Xa. To discover whether factor V and
factor VIII could be activated by factor Xa in plasma at a
concentration approaching the amount of factor X present in
plasma, we added 100 nmol/L purified human factor Xa to
plasma incubated for eight minutes with thromboplastin
(1/30 vol/vol), CaCl2 (20 mmol/L), and hirudin (2 zmol/
L). Before addition of factor Xa, no factor Va, factor Villa,
or thrombin activities could be detected. The endogenous
factor Xa concentration was 2 nmol/L. After addition of
factor Xa, samples were removed and assayed for factor Va,
factor Villa, and thrombin. No amidolytic thrombin activity
could be detected. Up to five minutes after addition of factor
Xa, the amounts of factor Va and VIlla were below the
detection limits of the assays, 0.2 pmol/L and 2 pmol/L,
respectively (ie, < 1% of the plasma factor V and <5% of the
plasma factor VIII was activated.
DISCUSSION
Investigators have explained their findings regarding the
effects of the anticoagulant drug heparin on the intrinsic
pathway of blood coagulation by assuming that small
amounts of factor Xa are able to activate factor VIII and
factor V.2”23 Although thrombin might be the most efficient
activator of both cofactors,’2 thrombin is also the end product
of the coagulation process. Therefore, a (partial) activation
of factor V or factor VIII by factor Xa earlier in coagulation
could amplify thrombin generation by inducing small
amounts of thrombin which then through a positive feedback
mechanism in turn activates factor VIII and factor V. In the
case of heparin, when thrombin activity is blocked, factor Xa
activation of factors V and VIII may become an important
amplification reaction.23 However, to our knowledge, that
factor VIII and factor V activation by factor Xa is indeed
essential to attain “physiologic” rates of factor Xa and
thrombin generation in plasma has never been demon-
strated.
In this study, we determined the relative contribution of
factor Xa and thrombin to activation of the nonenzymatic
protein cofactors factor VIII and factor V in plasma. Prelim-
mary studies on the intrinsic pathway of blood coagulation
revealed that factor Xa generation was strongly controlled by
specific thrombin inhibitors like hirudin. Because thrombin
and factor Xa generation cannot be separated, we could not
assess the relative contribution of thrombin and factor Xa
generation to activation of factor V and factor VIII when
plasma clotting was initiated by addition of factor IXa (T.
Lindhout and J. Pieters, unpublished observations).
Therefore, the plasma was triggered with thromboplastin
at a concentration high enough to limit the activation reac-
tions to the extrinsic pathway.#{176} We developed a very specific
assay to monitor generation of factor VIlla in plasma,
making use of the fact that (human) factor VIlla is able to
catalyze (bovine) factor X activation by (bovine) factor IXa
in the presence of phospholipids and calcium. A sensitive
assay for determination of factor Va generation in plasma
was developed during earlier studies.#{176}
Generation of factor Va in thromboplastin-activated
plasma follows generation of thrombin and shows a maxi-
mum at one minute. However, because factor Xa is also
generated at that time, it is not clear whether thrombin or
factor Xa is the activator of factor V in this system. To obtain
a thrombin generation independent of free factor Xa genera-
tion, we added hirudin to the plasma in several concentra-
tions. The thrombin generation curve obtained was indeed
dependent on the hirudin concentration used, whereas the
factor Xa generation curve was not influenced by hirudin.
When we determined the generation of factor Va in this
hirudinized plasma, it appeared to parallel the generation of
thrombin but not that of factor Xa. Moreover, addition of a
high amount of factor Xa to thromboplastin-activated
plasma containing hirudin (2 .tmol/L) did not cause any
activation of factor V. Factor VIlla generation was also
monitored and entirely paralleled thrombin generation.
Addition of a high amount of factor Xa did not induce factor
VIlla generation.
The results of our study using plasma as a physiologic
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environment for coagulation and thromboplastin as a clotting
trigger show that under these conditions thrombin is the only
activator of the factors V and VIII. The mechanism of
plasma clotting evolving from our results is one in which
factor X is activated by the TF factor VII(a) complex. This
prothrombin into thrombin, which then is able to activate
factor VIII and factor V. Only then are sufficient amounts of
thrombin generated to ensure proper clotting. The conclu-
sions derived from this study once again emphasize the
central role of thrombin in the overall process of in vitro
initially present factor Xa is able, at a low rate, to convert blood coagulation.
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